Status:
COMPLETED
Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Etablissement Français du Sang
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The coronavirus disease 2019 (COVID-19) viral pneumonia is now a worldwide pandemic caused by the Severe acute respiratory virus coronavirus 2 (SARS-CoV-2). The number of cases, and associated mortali...
Detailed Description
Hypothesize: early administration of convalescent plasma containing polyclonal neutralizing Abs may inhibit viral entry and replication (as recently suggested in vitro) and consequently blunt an early...
Eligibility Criteria
Inclusion
- Patients included in the CORIMUNO-19 cohort
- Onset of COVID19 functional signs \<8 days (plasma transfusion may occur up to day 10 of onset)
- Mild severity as described in the WHO scale
Exclusion
- Pregnancy
- Current documented and uncontrolled bacterial infection.
- Prior severe (grade 3) allergic reactions to plasma transfusion
Key Trial Info
Start Date :
April 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04345991
Start Date
April 15 2020
End Date
May 28 2021
Last Update
June 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SMIT, Saint Antoine hospital
Paris, France, 75012